

BIOSPECTRA

100 Majestic Way, Bangor, PA 18013 / www.biospectra.us

Effective Date:	7-Feb-2018	7-Feb-2021	: Date of Next Review
Prepared By:	Jamie Storm	16-001146 v.1.0	: Supersedes
QA/QC Approval:	Nicole Fisher	Dora Meissner	: Management Approval
Reason for Revision:	See Revision History in ensur		

GUANIDINE HYDROCHLORIDE

CERTIFICATE OF ANALYSIS

BIO EXCIPIENT GRADE / GH3220 – G100

LOT#: GH3220-007-0219

 $\text{NH}_2\text{C}(\text{NH})\text{NH}_2\cdot\text{HCl}$ ^ F.W. 95.53 g/mol. ^ CAS# 50-01-1

Manufacturing Date: 5/13/2018 Retest Date: 5/31/2020

Manufacturing Site: 1474 Rockdale Lane, Stroudsburg, PA 18360

Packaging Date: 2/20/2019

Packaging Site: 100 Majestic Way, Bangor PA, 18013

ANALYSIS		SPECIFICATIONS	RESULT
Absorbance (6M)	230 nm	0.2000 a.u. max.	0.1302 a.u.
	260 nm	0.0300 a.u. max.	0.0076 a.u.
	275 nm	0.0300 a.u. max.	0.0021 a.u.
Appearance and Color		White / Crystals	White / Crystals
Assay		99.5% min.	99.93%
Enzymes	DNase	None Detected	None Detected
	Protease	None Detected	None Detected
	RNase	None Detected	None Detected
Identification (IR)		Passes Test	Passes Test
Insoluble Matter		0.15% max.	0.0026%
Loss on Drying		0.5% max.	0.0495%
Melting Range		184-188°C	185.3 – 186.8 °C
Nitrate		0.01% max.	<0.01%
pH (6M)		4.5-6.0	4.97 @ 16.3 °C
Residue on Ignition		0.05% max.	<0.0100%
Solubility (6M)		Passes Test	Passes Test
Sulfate		0.01% max.	<0.01%
Trace Metals	Arsenic (As)	5 ppm max.	< 5 ppm
	Copper (Cu)	5 ppm max.	< 5 ppm
	Iron (Fe)	5 ppm max.	< 5 ppm
	Lead (Pb)	5 ppm max.	< 5 ppm

COUNTRY OF ORIGIN: U.S.A.

The information contained herein is the property of BioSpectra. The recipient is responsible for its safe-keeping, and the prevention of unauthorized appropriation, use, disclosure and copying.

TEST METHOD REFERENCE: DCN: 16-000493

INTENDED USE: Material Represented by this Certificate of Analysis is suitable to be used only as the following: ICH Q7 Compliant cGMP Manufactured Excipient, for use in further Manufacturing. The material represented by this Certificate of Analysis is not suitable to be used as an Active Pharmaceutical Ingredient, Drug Product or Household Item.

OVI STATEMENT: Based on the manufacturing process and the controlled handling and storage of this product, there is no potential for any of the residual solvents listed in the current USP method <467> Tables 1, 2, 3, or 4 to be present at the specified limits; furthermore, if tested this product would comply with USP/NF requirements.

Prepared by: Car Date: 2/22/19

Reviewed by: H. Bennett Date: 2/22/19